| REVIEW ARTICLE |
|
| Year : 2021 | Volume
: 7
| Issue : 2 | Page : 51-59 |
|
|
IL-23 blockers in dermatology
Shrichand G Parasramani1, Manasi Shirolikar2
1 Department of Dermo-Cosmetology, Lilavati Hospital and Research Centre, Mumbai, Maharashtra, India
2 Kaya Skin Clinic, Mumbai, Maharashtra, India
Correspondence Address:
Shrichand G Parasramani
Anisha Clinic, Mangal Sudha, SV Road, Khar, Mumbai 400052, Maharashtra
India
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/ijdd.ijdd_24_21
|
|
|
Interleukin-23 (IL-23) is the key regulatory cytokine in psoriasis, which stimulates differentiation, proliferation, and survival of T-helper 17 (Th17) cells. Specific targeting of IL-23–IL-17 inflammatory pathway has become an effective therapeutic approach to treat psoriasis. Clinical studies have shown that antibodies directed against the p19 subunit of IL-23 show equal or superior response as compared to when both IL-12 and IL-23 are inhibited. Side effects of IL-12 inhibition are avoided. Tildrakizumab, guselkumab, and risankizumab are antibodies that target the p19 subunit of IL-23. These newer IL-23 blockers give high PASI response and are easy to administer once in 8–12 weeks. A comparison of these three drugs from different trials is carried out in this review with the help of bar charts. There are no head-to-head comparative trials of these monoclonal antibodies. |
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
